China's Tianjin CanSino Biotechnology Inc. to Mass Produce Ebola Vaccine

Tianjin CanSino Biotechnology Inc., a private Chinese biotechnology company, plans to mass produce a vaccine against the Ebola virus developed by Chinese military scientists. The company has started construction of an industry base to produce the vaccine in the Tianjin Economic and Technological Development Area.

Investment into the base totals 2 billion yuan (about $317 million) and construction will be complete by September 2018. The base also produces vaccines against other infectious diseases including pneumonia, meningitis and tuberculosis. The annual production is around 200 million vaccines.

Ebola Virus Disease | Ebola Hemorrhagic Fever: Cause Symptoms Diagnosis Treatment
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have identified five types of Ebola or Ebola hemorrhagic fever virus.

Developed by a team of biotech scientists with the Chinese Academy of Military Medical Sciences, the Ebola vaccine is based on the 2014 mutant gene type and in the form of freeze-dried powder, which can remain stable for at least two weeks in temperatures of up to 37 degrees Celsius. Experts suggest that it is suitable for the tropical climate in West African countries, where the deadly epidemic outbreak has killed more than 11,297 people since 2014.

According to the ministry of health of Sierra Leone, one of the three most affected countries along with Liberia and Guinea, the Ebola vaccine has proven to be clinically safe. Since the disease outbreak, China has offered 120 million US dollars of aid and 500 medical staff and experts to affected countries.

Source-IANS

Ebola Vaccine Shows 100% Efficacy in Trials, the End of the Deadly Virus Could be Near
Analysis of an Ebola trial being implemented at Guinea shows that the vaccine, VSV-EBOV, developed by the Public Health Agency of Canada, is highly effective.

World Support for Ebola: US$35 Million Funding from King Abdallah of Saudi Arabia
Zaire ebolavirus is commonly known as Ebola. It was previously known as ebola haemorrhagic fever and is a deadly human illness.

China-Made Ebola Vaccine Permitted for Overseas Phase Two Clinical Trials
The Chinese Ebola vaccine has three major features- the vaccine is the first based on the Ebola virus strain responsible for the West African outbreak in 2014.